1143 LABORATORY ASSESSMENT OF PROTECTION AGAINST H. INFLUENZAE TYPE B (Hib)

Licensure of a Haemophilus influenzae type b (Hib) vaccine (Hiberix) and updated recommendations for use of Hib vaccine.

On August 19, 2009, the Food and Drug Administration (FDA) licensed Hiberix (GlaxoSmithKline Biologicals, Rixensart, Belgium), a Haemophilus influenzae type b (Hib) conjugate vaccine composed of H. influenzae type b capsular polysaccharide (polyribosyl-ribitol-phosphate [PRP]) conjugated to inactivated tetanus toxoid (PRP-T). Hiberix is licensed for use as the booster (final) dose of the Hib va...

Introduction of Haemophilus influenzae type b (Hib) as pentavalent(DPT-HepB-Hib) vaccine in two states of India.

Quality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis/Hib combination vaccines.

It has been repeatedly observed that mixing Haemophilus influenzae type b (Hib) conjugate vaccines with acellular pertussis-containing vaccines (diphtheria-tetanus-acellular pertussis [DTPa]) resulted in a reduced magnitude of the anti-polyriboseribitolphosphate antibody response compared to that obtained when Hib vaccines were administered separately and not mixed. Nevertheless, the quality an...

Immune response of adults with secondary immunodeficiency to pediatric Haemophilus influenzae type b (Hib) vaccine

Background Patients with chronic renal failure (CRF) develop secondary immunodeficiency as a result of the uremic state and its metabolic consequences, along with a negative impact of the dialysis procedure on the immune system. Such patients are therefore at high risk for septicemia and other severe infections. In non-vaccinated adults, protection against Haemophilus influenzae type b (Hib) is...

Quality of the Haemophilus influenzae type b antibody response induced by DTPa/Hib combination vaccines

It has been repeatedly observed that mixing Haemophilus influenzae type b (Hib) conjugate vaccines with acellular pertussis-containing vaccines (DTPa) resulted in a reduced magnitude of the anti-PRP (polyriboseribitolphosphate) antibody response, compared to that obtained when Hib vaccines are administered separately and not mixed. Nevertheless, quality and functionality of the immune responses...